Clinical Trials

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

15 enrolled 18 charts

Breast Neoplasms

NCT06974929 2025-12-30

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

80 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

40 enrolled

Breast Neoplasms

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

528 enrolled

Breast Neoplasms

NCT03774472 2025-02-17

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

15 enrolled 11 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT04282031 2024-08-07

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

BreastOther solid neoplasm

224 enrolled

Advanced Solid Tumor

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 1/2 Terminated

3 enrolled

HER2-positive Breast Cancer

NCT05705505 2023-12-12

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

60 enrolled

Gynecologic

Endometrioid Endometrial Cancer

NCT03481998 2023-11-21

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

104 enrolled

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

42 enrolled 16 charts

Breast Neoplasms

NCT00634634 2023-11-09

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

52 enrolled 14 charts

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

59 enrolled

Breast Neoplasms

NCT01791985 2022-08-22

RADICAL

52 enrolled 17 charts

Breast Neoplasms

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

95 enrolled

Breast Neoplasms

NCT00290745 2020-12-04

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

79 enrolled 15 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04488107 2020-07-27

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

78 enrolled

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast Neoplasms

NCT01105312 2017-06-27

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

28 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01082068 2016-06-03

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

72 enrolled